Following the restructuring of Lifecare including the acquisition of the two
operational German subsidiaries Lifecare NanoBioSensors and Lifecare
Laboratories, the Lifecare Board of Directors, management, and key personnel
have conducted an inspiring and productive workshop in Mainz, Germany. Due to a
current high demand for Covid PCR testing, Lifecare Laboratories experiences an
extraordinarily high activity level, generating revenue, while Lifecare
NanoBioSensors has increased its operational capacity. We are planning for
additional expansion of employees at our Norwegian headquarter and our planned
technical pathway stays unchanged.         

Read more in the Lifecare February newsletter:
https://lifecare.no/news/information-from-lifecare-february-2022/

This is Lifecare
Lifecare is a Bergen-based technology company developing a miniaturized
implantable long-term sensor for correct and continuous monitoring of blood
sugar in people with diabetes. The Company's patented technology also has the
potential for use in various biomarkers. Lifecare AS is listed on Euronext
Growth (LIFE).

Further information Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no,
+47 40 05 90 40 

This stock exchange announcement was published by Kine Hereid, Investor
Relations at Lifecare AS, on 28.02.22 at 09:00 CET.